Rituximab



Description générale

Rituximab is a monoclonal antibody used in treatment protocols for lymphomas and leukaemia, as well as various autoimmune inflammatory diseases.

INN	Rituximab
Codes ATC	L01FA01
Type de médicament	Biological agent
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994) pour Diffuse large B-cell lymphoma, not otherwise specified Modifié en 2015 (TRS 994) pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Modifié en 2015 (TRS 994) pour Follicular lymphoma Modifié en 2023 (TRS 1049) pour Multiple sclerosis Modifié en 2023 (TRS 1049) pour Burkitt lymphoma including Burkitt leukaemia
Wikipédia	Rituximab
DrugBank	Rituximab

Recommandations

Section Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Section Medicines for multiple sclerosis

- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

Multiple sclerosis